BR112017000800A8 - Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico - Google Patents

Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico

Info

Publication number
BR112017000800A8
BR112017000800A8 BR112017000800A BR112017000800A BR112017000800A8 BR 112017000800 A8 BR112017000800 A8 BR 112017000800A8 BR 112017000800 A BR112017000800 A BR 112017000800A BR 112017000800 A BR112017000800 A BR 112017000800A BR 112017000800 A8 BR112017000800 A8 BR 112017000800A8
Authority
BR
Brazil
Prior art keywords
oxide nanoparticles
radiation
combination
cerium oxide
chemotherapy
Prior art date
Application number
BR112017000800A
Other languages
English (en)
Other versions
BR112017000800A2 (pt
Inventor
Baker Cheryl
Original Assignee
Biocurity Holdings Inc
Biocurity Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocurity Holdings Inc, Biocurity Pharmaceuticals Inc filed Critical Biocurity Holdings Inc
Publication of BR112017000800A2 publication Critical patent/BR112017000800A2/pt
Publication of BR112017000800A8 publication Critical patent/BR112017000800A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

RATAMENTO DO CÂNCER COM UMA COMBINAÇÃO DE RADIAÇÃO, NANOPARTICULAS DE ÓXIDO DE CÉRIO, E UM AGENTE QUIMIOTERÁPICO. A presente invenção é direcionada a métodos de tratamento de câncer com uma combinação de radiação, nanopartículas de óxido de cério e pelo menos um agente quimioterápico. As nanopartículas de óxido de cério (CONPs) são cristais de tamanho nanométrico de óxido de cério, tipicamente variando entre cerca de um nanômetro a cerca de 20 nanômetros na dimensão mais longa. Os presentes métodos utilizam nanopartículas de óxido de cério para aumentar a morte das células de câncer induzidas por radiação e induzidas pela quimioterapia e também reduzir a toxicidade associada à radioterapia e à quimioterapia.
BR112017000800A 2014-07-17 2015-07-17 Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico BR112017000800A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025861P 2014-07-17 2014-07-17
US62/025,861 2014-07-17
PCT/US2015/040869 WO2016011328A1 (en) 2014-07-17 2015-07-17 Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

Publications (2)

Publication Number Publication Date
BR112017000800A2 BR112017000800A2 (pt) 2018-07-03
BR112017000800A8 true BR112017000800A8 (pt) 2023-04-25

Family

ID=55079076

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000800A BR112017000800A8 (pt) 2014-07-17 2015-07-17 Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico

Country Status (9)

Country Link
EP (2) EP3169312B1 (pt)
JP (2) JP6706255B2 (pt)
CN (2) CN106604719B (pt)
AU (1) AU2015289504B2 (pt)
BR (1) BR112017000800A8 (pt)
CA (1) CA2955384C (pt)
MX (1) MX2017000578A (pt)
RU (2) RU2704811C2 (pt)
WO (1) WO2016011328A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512761B2 (en) 2009-12-02 2019-12-24 Renovorx, Inc. Methods for delivery of therapeutic materials to treat pancreatic cancer
WO2014197362A1 (en) 2013-06-03 2014-12-11 Ramtin Agah Devices, methods and kits for delivery of therapeutic materials to a pancreas
EP3169312B1 (en) * 2014-07-17 2020-09-02 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
WO2017174437A1 (en) * 2016-04-05 2017-10-12 Hospital Clínic De Barcelona Ceria nanoparticles for use in the treatment of hepatocellular carcinoma
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3609329A4 (en) * 2017-04-12 2021-03-17 Bhagwandin, Vikash J. COMPOSITIONS, PACKAGED MEDICINAL PRODUCTS AND METHODS OF USE OF POSACONAZOLE FOR RESISTANT TUMORS Awareness
US10695543B2 (en) 2017-05-18 2020-06-30 Renovorx, Inc. Methods for treating cancerous tumors
US11052224B2 (en) 2017-05-18 2021-07-06 Renovorx, Inc. Methods for treating cancerous tumors
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
KR102102535B1 (ko) * 2018-07-26 2020-04-21 서울대학교산학협력단 방사선 보호 나노입자
EP3856150A4 (en) * 2018-09-28 2023-02-22 The Regents Of The University Of Colorado METHOD OF PREVENTION AND TREATMENT OF LUNG INFLAMMATION AND FIBROSIS
RU2699670C1 (ru) * 2018-11-16 2019-09-09 Объединенный Институт Ядерных Исследований (Оияи) Способ повышения частоты образования двунитевых разрывов днк в клетках человека при действии ионизирующих излучений в условиях влияния радиомодификаторов
EP4125364A1 (en) * 2020-04-30 2023-02-08 University of Central Florida Research Foundation, Inc. Dispensable nanoparticle based composition for disinfection
WO2023025312A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 使用th-302治疗parp抑制剂耐药的患者
CN117651548A (zh) 2021-08-27 2024-03-05 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099798A (en) 1997-10-31 2000-08-08 Nanogram Corp. Ultraviolet light block and photocatalytic materials
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2007002662A2 (en) * 2005-06-27 2007-01-04 Edward Via Virginia College Of Osteopathic Medicine Anti-inflammatory, radioprotective, and longevity enhancing capabilities of cerium oxide nanoparticles
PE20091180A1 (es) * 2007-12-27 2009-08-26 Infinity Pharmaceuticals Inc Tratamientos terapeuticos contra el cancer
WO2009132277A1 (en) * 2008-04-25 2009-10-29 The Board Of Regents Of The University Of Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US9393439B2 (en) * 2010-03-01 2016-07-19 Intraop Medical Corporation Radiotherapy combined with hypoxic cell sensitizers
US20120251496A1 (en) * 2011-03-31 2012-10-04 Telik, Inc. Ezatiostat for treating multiple myeloma
CA2869554A1 (en) * 2012-04-04 2013-10-10 Duke University Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury
IN2014DN10550A (pt) * 2012-06-13 2015-08-21 Cerion Entpr Llc
US9884886B2 (en) * 2012-12-06 2018-02-06 Merck Sharp & Dohme Disulfide masked prodrug compositions and methods
US10463734B2 (en) * 2014-04-25 2019-11-05 The Regents Of The University Of Michigan Nanoparticle therapy in cancer
EP3169312B1 (en) * 2014-07-17 2020-09-02 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
GB201506381D0 (en) * 2015-04-15 2015-05-27 Isis Innovation Embolization particle

Also Published As

Publication number Publication date
JP6706255B2 (ja) 2020-06-03
EP3169312B1 (en) 2020-09-02
RU2019133284A (ru) 2019-12-05
CN106604719B (zh) 2019-11-26
JP2020158507A (ja) 2020-10-01
CN111184733A (zh) 2020-05-22
JP2017521499A (ja) 2017-08-03
MX2017000578A (es) 2017-07-20
CA2955384A1 (en) 2016-01-21
BR112017000800A2 (pt) 2018-07-03
RU2017104909A3 (pt) 2019-01-28
AU2015289504A1 (en) 2017-02-23
AU2015289504B2 (en) 2020-12-17
RU2017104909A (ru) 2018-08-17
CA2955384C (en) 2024-03-12
WO2016011328A1 (en) 2016-01-21
EP3169312A1 (en) 2017-05-24
RU2704811C2 (ru) 2019-10-31
EP3169312A4 (en) 2017-12-27
EP3628308A1 (en) 2020-04-01
CN106604719A (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
BR112017000800A8 (pt) Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CL2018002787A1 (es) Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.
CL2017003457A1 (es) Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor.
BR112019000327A8 (pt) Anticorpo para anticlaudina 18a2 e uso do mesmo
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
PE20170392A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX350588B (es) Composiciones de alcanos semifluorados.
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
UY35082A (es) Sustancia portadora de oxigeno basada en la hemoglobina que contiene una composicion farmaceutica para el tratamiento del cancer y la la prevencion de la recurrencia del cancer
BR112017027887A2 (pt) partículas e suspensões radioterapêuticas
AR112103A1 (es) Compuestos para el tratamiento de tnbc
BR112018076639A2 (pt) quimioterapias de combinação
UY37897A (es) ARNi VARIANTE
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
BR112017012435A2 (pt) guindaste sobre rodas e métodos de autodesmontagem e automontagem para pernas de suporte do mesmo
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
BR112015024621A8 (pt) usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi
CL2016000026A1 (es) Nuevos derivados de azabencimidazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BIOCURITY PHARMACEUTICALS INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]